Scarica l'app Stockscreener
46.29
3.88%
-1.87
Uniqure Nv Borsa (QURE) Ultime notizie
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval - TradingView
UniQure surges on plans to seek US nod for gene therapy - MSN
uniQure reports mixed results from epilepsy gene therapy trial - Investing.com UK
uniQure reports mixed results from epilepsy gene therapy trial By Investing.com - Investing.com Australia
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now - InvestorPlace
uniQure’s epilepsy gene therapy showed seizure drops in 3 patients - Stock Titan
What Caused uniQure's Dramatic Stock Plunge - Kavout
uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy - Benzinga
QURE Maintained by Goldman Sachs -- Price Target Raised to $46 - GuruFocus
QURE Maintained by Leerink Partners -- Price Target Raised to $7 - GuruFocus
uniQure N.V. (NASDAQ: QURE) insider sells 164,429 shares across June filings - Stock Titan
QURE Upgraded by Barclays -- Price Target Raised to $65 - GuruFocus
Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting - Barchart.com
QURE Maintained by RBC Capital -- Price Target Raised to $65.00 - GuruFocus
UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says - marketscreener.com
uniQure receives FDA pathway for Huntington’s disease therapy - Investing.com UK
Worldwide Healthcare Trust PLCPortfolio Holding uniQure N.V. Announces Filing Plans with U.S. Food & Drug Administration - Sharecast.com
uniQure (QURE) Receives Upgrade from Barclays with Increased Pri - GuruFocus
uniQure receives FDA pathway for Huntington’s disease therapy By Investing.com - Investing.com Canada
UniQure: AMT-130's FDA Path Reaffirms My Bull Case (NASDAQ:QURE) - Seeking Alpha
Barclays upgrades uniQure stock rating on Huntington’s timeline By Investing.com - Investing.com Australia
Barclays upgrades uniQure stock rating on Huntington’s timeline - Investing.com
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $46 to $70 - 富途牛牛
uniQure stock rating reiterated at Buy by H.C. Wainwright on FDA update - Investing.com
Leerink raises uniQure stock price target to $70 on FDA reversal - Investing.com
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RBC Raises Price Target on uniQure to $65 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
uniQure shares steady after FDA momentum, Huntington’s filing on radar - TechStock²
uniQure shares leap as FDA opens door to gene therapy filing - The Pharma Letter
Uniqure NV (QURE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Uniqure NV (QURE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
UniQure shares soar after FDA reversal on its Huntington’s therapy - MSN
QURE’s 78% FDA Shock Rally Puts uniQure Back in the Huntington’s Race - FXLeaders
Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch - RTTNews
UniQure (QURE) Gains Momentum After FDA Reversal on Gene Therapy - GuruFocus
uniQure reversal puts natural-history controls back in play for rare neuro - BioCentury
[144] uniQure N.V. SEC Filing - Stock Titan
UniQure (QURE) Soars 78% on AMT-130 Progress - Insider Monkey
UniQure soars as Cantor upgrades on plans to seek gene therapy nod - MSN
UniQure positioned for gains after FDA supports accelerated approval path for AMT-130 - MSN
QURE Stock Soars As FDA Backs Gene Therapy Pathway - timothysykes.com
uniQure (QURE) director exercises options, sells 10,000 shares under 10b5-1 plan - Stock Titan
Tax-driven share sale by uniQure (NASDAQ: QURE) chief legal officer - Stock Titan
UniQure (NASDAQ: QURE) notice to sell 5,295 Ordinary Shares - Stock Titan
Insider sells 11,685 UniQure shares under 10b5-1 plan (QURE) - Stock Titan
Goldman Sachs reiterates Neutral on uniQure stock after FDA meeting By Investing.com - Investing.com Nigeria
uniQure (QURE) Plans U.S. Marketing Application for Gene Therapy AMT-130 - GuruFocus
uniQure (QURE) Shares Surge Following FDA Clearance for Gene The - GuruFocus
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE) - Seeking Alpha
Mizuho reiterates Outperform on uniQure stock, $35 target By Investing.com - Investing.com Nigeria
UniQure Shares Jump After Plans Announced for FDA BLA Submission for AMT-130 in Huntington's Disease - marketscreener.com
UniQure Shares Soar on Go-to-Market Plan - 富途牛牛
Regenxbio stock gains after FDA's UniQure U-turn (RGNX:NASDAQ) - Seeking Alpha
Goldman Sachs reiterates Neutral on uniQure stock after FDA meeting - Investing.com
Mizuho reiterates Outperform on uniQure stock, $35 target - Investing.com
uniQure N.V. (QURE) Stock: Rises as FDA Supports AMT-130 Filing Path - parameter.io
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $50 - Moomoo
uniQure stock upgraded at Cantor on FDA decision (QURE:NASDAQ) - Seeking Alpha
uniQure stock set to rise after FDA backs BLA pathway for AMT-130 - Investing.com
uniQure (QURE) Receives Positive FDA Feedback on AMT-130 Trial - GuruFocus
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):